Response criteria for intraocular retinoblastoma: RB‐RECIST

• Published in: Pediatric blood & cancer Vol. 68; no. 5; pp. e28964 - n/a
• Main Authors: Berry, Jesse L., Munier, Francis L., Gallie, Brenda L., Polski, Ashley, Shah, Sona, Shields, Carol L., Gombos, Dan S., Ruchalski, Kathleen, Stathopoulos, Christina, Shah, Rachana, Jubran, Rima, Kim, Jonathan W., Mruthyunjaya, Prithvi, Marr, Brian P., Wilson, Matthew W., Brennan, Rachel C., Chantada, Guillermo L., Chintagumpala, Murali M., Murphree, A. Linn
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2021
• Subjects: Cancer; Clinical trials; Hematology; Humans; imaging; Multimodal Imaging - methods; ocular oncology; Oncology; Pediatrics; response criteria; Response Evaluation Criteria in Solid Tumors; Retina; Retinal Neoplasms - diagnostic imaging; Retinoblastoma; Retinoblastoma - diagnostic imaging; Solid tumors; Tumors; ultrasonography; ocular oncology; response criteria; clinical trials; retinoblastoma; ultrasonography; imaging
• ISSN: 1545-5009; 1545-5017
• DOI: 10.1002/pbc.28964

Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response—such as progression‐free survival—to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.